Navigation Links
ANI Pharmaceuticals Announces an Agreement for the Development and Marketing of an Oral Soft Gel Prescription Product with Sofgen Pharmaceuticals
Date:8/12/2013

BAUDETTE, Minn., Aug. 12, 2013 /PRNewswire/ -- ANI Pharmaceuticals (NASDAQ: ANIP) today announced that it has signed a binding letter of intent for the development of an oral soft gel prescription product with Sofgen Pharmaceuticals ("Sofgen.") The product, indicated for cardiovascular health, will be the subject of an Abbreviated New Drug Application ("ANDA") filing. Sofgen will be responsible for the development, manufacturing and regulatory submission of the product and ANI will be responsible for marketing and distribution in the United States.

Arthur S. Przybyl, ANI's President and CEO stated, "I am pleased to have entered into this collaboration with Sofgen for an oral soft gel drug.  In addition to our internal product development efforts, we will continue to pursue opportunities through external partnerships and acquisitions in order to leverage our core capabilities in manufacturing and marketing.  We are fortunate to have such a high quality partner in Sofgen."

About ANI

ANI is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. In two facilities with combined manufacturing, packaging and laboratory capacity totaling 173,000 square feet, ANI manufactures oral solid dose products, as well as liquids and topicals, including narcotics and those that must be manufactured in a fully contained environment due to their potency and/or toxicity. ANI also performs contract manufacturing for other pharmaceutical companies. Over the last two years ANI has launched three new products and has twelve products in development. ANI's targeted areas of product development include narcotics, anti-cancers and hormones (potent compounds), and extended release niche generic product opportunities. ANI's other products include an FDA-approved testosterone gel, which is licensed to Teva Pharmaceuticals USA. For more information please visit our website www.anipharmaceuticals.com.

About Sofgen

Sofgen is a dynamic company established in Florida as a specialized developer and manufacturer of niche pharmaceutical products with high barriers to entry. Sofgen is part of the Procaps Group, which has a manufacturing network with facilities throughout North and South America, with a wealth of experience in soft capsules and related delivery technologies, servicing customers within the health sector in 50 different countries around the globe. For more information please visit our website www.sofgenpharma.com

Forward-Looking Statements

This news release contains forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about ANI's plans, objectives, expectations and intentions with respect to future operations and products, the anticipated financial position, operating results and growth prospects of ANI and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "plans," "potential," "future," "believes," "intends," "continue," other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause ANI's actual results to be materially different than those expressed in or implied by such forward-looking statements. Uncertainties and risks include the risk that ANI may in the future fail to meet NASDAQ listing requirements; general business and economic conditions; ANI's need for and ability to obtain additional financing; the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; and the marketing success of ANI's licensees or sublicensees. More detailed information on these and additional factors that could affect ANI's actual results are described in ANI's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K, most recent quarterly report on Form 10-Q, as well as its proxy statement/prospectus, filed with the Securities and Exchange Commission on May 8, 2013. All forward-looking statements in this news release speak only as of the date made and are based on ANI's current beliefs and expectations. ANI undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

For more information about ANI, please contact:
Arthur S. Przybyl
(218) 634-3608
arthur.przybyl@anipharmaceuticals.com


'/>"/>
SOURCE ANI Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals Announces Continuance
2. Inovio Pharmaceuticals Reports 2013 Second Quarter Financial Results
3. ANI Pharmaceuticals Reports Net Revenues of $6.2 million and adjusted non-GAAP EBITDA of $1.2 Million for the Second Quarter Ended June 30, 2013
4. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for Second Quarter 2013
5. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity Growth Conference
6. EpiCept Stockholders Overwhelmingly Approve Final Conditions to Merger with Immune Pharmaceuticals Ltd.
7. Isis Pharmaceuticals to Present at the Canaccord Genuity 33rd Annual Growth Conference
8. Valeant Pharmaceuticals Reports 2013 Second Quarter Financial Results
9. Cadence Pharmaceuticals To Present At The 2013 Wedbush PacGrow Life Sciences Management Access Conference On August 13, 2013
10. Alexza Pharmaceuticals to Present at the 2013 Wedbush Life Sciences Management Access Conference
11. Avanir Pharmaceuticals Reports Fiscal 2013 Third Quarter Financial and Business Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... 2017  EnteroMedics Inc. (NASDAQ: ETRM ... technology to treat obesity, metabolic diseases and other ... underwritten public offering of units for gross proceeds ... and commissions and offering expenses payable by EnteroMedics. ... A Units, priced at a public offering price ...
(Date:1/18/2017)...  Adaptive Sound Technologies, Inc. (ASTI), the leading supplier ... Hyatt Place Nashville/Downtown to deliver the best sleep experience ... machines in over two hundred of its guest rooms. ... of having a great stay is sleeping well," said ... Nashville/Downtown. "We,re pleased to be able to offer our ...
(Date:1/18/2017)... 18, 2017  Dermata Therapeutics, LLC, a biotechnology ... a variety of dermatological diseases, announces dosing the ... a Phase 2 acne rosacea study. DMT210 is ... proinflammatory cytokines in the skin responsible for the ... This clinical trial, DMT210-003, is a ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... ... agency which serves Lawrenceville, New Jersey and the surrounding area, is inaugurating ... lateral sclerosis (ALS), more commonly known as Lou Gehrig's disease or motor neurone ...
(Date:1/19/2017)... , ... January 18, 2017 , ... The CHP suggests ... during a rain storm by slowing down and increasing the space between themselves and ... Los Angeles based car accident attorney Raymond R. Hassanlou notes that, rain or shine, ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... styled text designs that will simplify the editing process for all media productions," ... Basics is a package of 30 simplistically styled self-animating paragraphs designed for multi-lined ...
(Date:1/18/2017)... Austin, TX (PRWEB) , ... January 18, 2017 , ... ... million people opened a global discussion about the benefits of fidgeting to relieve stress ... Lyon and Jym Daniel. Their Think Ink Pen had just completed a successful ...
(Date:1/18/2017)... SAN JOSE, Calif, USA; and SHANGHAI, China – , ... ... January 18, 2017 -- Global public health organization NSF International ... V (pentavalent arsenic) to NSF/ANSI 53: Drinking Water Treatment Units ... treatment units. This certification verifies that MicroCeramics’ NanoNose Pitcher Filter ...
Breaking Medicine News(10 mins):